Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy

jghe
Website

Published by The Indonesian Society for Digestive Endoscopy

ISSN : 14114801 EISSN : 23028181 DOI : -

Core Subject : Health,

Medicine & Pharmacology

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy is an academic journal which has been published since 2000 and owned by 3 Societies: The Indonesian Society of Gastroenterology; Indonesian Association for the Study of the Liver; The Indonesian Society for Digestive Endoscopy. The aim of our journal is to advance knowledge in Gastroenterology, Hepatology, and Digestive Endoscopy fields. We welcome authors for original articles, review articles, and case reports in the fields of Gastroenterology, Hepatology, and Digestive Endoscopy.

Arjuna Subject : Kedokteran - Ilmu Pencernaan

Articles 771 Documents

43 44 45 46 47

Mirizzi’s Syndrome Fachrull -; Anggilia Stephanie; E Mudjaddid
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 16, No 3 (2015): VOLUME 16, NUMBER 3, December 2015
Publisher : The Indonesian Society for Digestive Endoscopy

Mirizzi’s syndrome was an obstruction caused by gallstone located in gallbladder neck (or cystic duct) or outside gallbladder that caused a dilatation of gallbladder and narrowing of adjacent duct, sometimes with the presence of cholecystocholedochal fistula. Mirizzi’s syndrome was a rare complication of gallbladder stone. We reported a 42 years old woman complained progressive icteric sclera. Patients also complained dark urine and light stool. During physical examination, we found an icteric sclera, pain in right upper quadrant (visual analogue scale/VAS 3), and generalized icterus (greenish yellow). Complete examination revealed a Mirizzi’s syndrome.

Chronic Viral Hepatitis: Etiology, Pathogenesis of Liver Damage and Mechanisms of Persistence Irwan Setiabudi
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 5, ISSUE 2, August 2004
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/52200458-61

Chronic hepatotropic viruses commonly evade the antiviral defence systems of the body and cause a long - lasting persistent infection. The prolonged nature of the infection ensures that every infected person has ample opportunity to transmit the virus to others, allowing many millions of people world- wide to become infected. Three viruses commonly cause chronic hepatitis B virus, hepatitis C virus and hepatitis Delta virus. Virus specific CD8 T cells of the host, represent the main effector cells against viral infection. Where as the antiviral cytokines have a major role in the control of viral replication (non-cytolytic inhibition). To cause persistent infection, a virus must avoid the host defences and that hepatotropic viruses have developed elaborate strategies to achieve this. In the case of hepatitis B virus, two proteins are involved in the inhibition of the host defences; those are the core protein that has been shown to inhibit the production of interferon and the polymerase protein has been shown to inhibit its effect. Where as in the case of hepatitis C virus, the NS5A and E2 protein reduce the effect of interferon by inhibiting the antiviral kinase. In order to survive and persistent in the liver, the hepatotropic viruses must be able to avoid both arms of the immune system, either by mutation of viral proteins or by preventing activation of the immune system. Keywords: Hepatotropic viruses, core proteins, interferon

Higher Risk of Hepatocellular Carcinoma Progression in the Population of Untreated Immune-Tolerant Phase Chronic Hepatitis B Patients: An Evidence Based Alessa Fahira; Irsan Hasan
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 21, No 1 (2020): VOLUME 21, NUMBER 1, April 2020
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Hepatitis B infection is a major health problem worldwide, currently occurring in 350-400 millions of people. If not treated properly, hepatitis B infection may progess into chronic hepatitis B (CHB)—which may developed into hepatocelullar carcinoma (HCC). The first phase of CHB, the immune-tolerance (IT) phase, is marked with minimal necroinflammatic activity and a lower risk in the development of a more chronic liver condition, by hence antiviral therapy is not recommended. Recent studies however, shows that there are apparently histological activity and immune specific response towards HBV, accompanied by extensive clonal expansion of hepatitis in the IT phase, hence questioning its risk for the development of HCC. This evidence-based case report is meant to comprehensively review the effect of antiviral treatment in IT-phase CHB patients from available studies.Method: Pubmed, ProQuest, Cochrane, Scopus, Sciencedirect and EBSCOhost were comprehensively searched for systematic review and cohort prognostic researches studying the impact of anti-virals treatment for CHB patients in IT-phase. Three studies were selected and critically appraised. Data were then summarized descriptively.Results: The three studies included in this study were retrospective cohort studies. One study stated that the treated IT-phase group had significantly reduced risk for HCC (HR = 0.234; log-rank p = 0.046), compared to the untreated IT-phase group. One study found that untreated IT phase is asscociated with significantly higher risk of HCC (HR = 2.54; 95% CI: 1.54 to 4.18; p 0.001) compared to the treated immune-active (IA) phase group. The last study stated a higher adjusted hazard ratio (aHR) of the UIT in predicting HCC risk was 2.327 (95% CI 0.475–11.391; p = 0.297), if compared to the IA group.Conclusion: While studies shows apparent results regarding the treatment of CHB patients in the IT-phase and its benefit in reducing cumulative incidence of HCC, its clinical advantage is soon to be discovered. The results were inconclusive, and the initiation of treatment in CHB patients within the IT-phase cannot yet be recommended until further research.

Colorectal Cancer Metastasis of and the Risk Factors Ahmad Soefyani; Abdul Aziz Rani; Marcellus Simadibrata; Murdani Abdullah; Ening Krisnuhoni
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 11, NUMBER 1, April 2010
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/11120107-10

Background: Colorectal cancer (CRC) is the fourth most prevalent cancer in the world and is positioned the second most common cancer in the United States. Patients with CRC in Indonesia showed a greater proportion. In Jakarta, 47.85% of CRC cases occur under the age of 45 years. The purpose of this study is to determine metastasis and the factors that influence colorectal cancer patients. Method: This study was conducted retrospectively from January 2003-December 2007 in Cipto Mangunkusumo hospital. Patients are eligible if they underwent colonoscopy, tumor biopsy, anatomical pathology, abdominal CT scan, abdominal ultrasonography, and radiology procedures. Result: Of all 1,615 patients who underwent colonoscopy procedure, 377 patients were diagnosed with colorectal cancer. Subject that met the criteria consist of 86 patients, where 56 (65.1%) male. Most aged 51-60 years old (26.7%), mean age 47.90 ± 14.53 years old. The tumor is most commonly located in the rectum and sigmoid 40 (46.5%), in which 18 (45%) among them had metastasized. Compared with male patients, female patients experienced more metastases, but not statistically significant. Among the patients with metastasized CRC, 42.3% of them 40 years old, 37.2% patients 41-60 years old, and 29.4% patients 60 years old. Well-differentiated CRC produce larger number of metastatic cases than poorly-differentiated CRC. Poorly-differentiated CRC tend to produce adjacent metastasis, and also happened in relatively young age in compared with well-differentiated cancer. Conclusion: There was significant correlation between younger age group with a poor degree of histopathologic differentiation. Patients with CRC consist of more male patients than female ones. Factors sex, age group, histopathologic subtypes, and tumor location was not associated with metastasis. Keywords: colorectal cancer, metastasis, well-differentiated, poorly-differentiated

Paradigm on Chronic Constipation: Pathophysiology, Diagnostic, and Recent Therapy Laurentius Aswin Pramono; Ahmad Fauzi; Ari Fahrial Syam; Dadang Makmun
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 13, NUMBER 3, Desember 2012
Publisher : The Indonesian Society for Digestive Endoscopy

ABSTRACTChronic constipation is a medical gastrointestinal problem which can degrade patient’s quality of life. So far, the shifting pathophysiologic mechanism to colonic neuropathology has not been supported by diagnostic facility and therapy. Target therapy for chronic constipation related to enteric nervous system is still limited to study. Currently, the discovery of neurotrophin-3 has not shown any significant development needed in daily clinical practice. Until now study related to endoscopic full-thickness biopsy has not been done in human and waiting for its applications in daily practice. Targeted therapy for chronic constipation which is related to enteric nervous system is still limited to study. The discovery of neurotrophin-3, although currently on clinical trial phase II, still not showing any significant contribution in daily clinical practice. New pathophysiologic mechanism shifting the ‘idiopathic’ paradigm or ‘functional’ to colonic neuropathology has not been met with diagnostic modalities and therapy based on this knowledge. Study regarding endoscopic full-thickness biopsy to help revealing this novel mechanism has not been done in human. Henceforth, until now applied studies pertinent to this subject are longing in order for enteric neuron etiology can be firmly established Thus, in the future, translational study is demandingly needed for a firm establishment of diagnostic and therapeutic modalities to its currently evolving pathophysiology. Keywords: chronic constipation, colon, enteric nervous system, neurotophin-3

Artificial Ascites in Radiofrequency Ablation for Liver Cancer Rino Alvani Gani
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 18, No 3 (2017): VOLUME 18, NUMBER 3, DECEMBER 2017
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Radio Frequency Ablation (RFA) is one of the treatment modality for liver tumor either as primary tumor as well as secondary malignancy. Occasionally, a good ablation can’t be performed due to the tumor location. To assists the ablation in this particular case, some fluid can be deposited inside the abdomen which is called as artificial ascites. The aim of this study is to report and evaluate the method of artificial ascites in RFAMethod: This was a case series study consist of 19 consecutive patients that had been treated with ultrasound-guided RFA using artificial ascites from 2014 to 2017.Result: Artificial ascites was successfully performed in all 19 patients (100%) with total of 53 hepatocellular carcinoma (HCC) lesions in 34 RFA’s sessions and tumor size ranges from 10mm to 50mm. Most of the tumors were primary tumor (14/19). 9 patients had single tumor and 10 patients had multiple tumors and most of the tumor were located in segment 5 (14/53). Artificial ascites was performed using 5% dextrose in water (D/W)solution ranging from 500ml to 1500ml. No adverse effect occurred during and after the procedure.Conclusion: Percutaneous RFA using artificial ascites technique was safe and effective fortreating HCC

Prevention and Management of Refeeding Syndrome Andika Indrarespati; Kaka Renaldi
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 17, No 3 (2016): VOLUME 17, NUMBER 3, December 2016
Publisher : The Indonesian Society for Digestive Endoscopy

Refeeding Syndrome is a syndrome which occurs as a result of food administration in poorly nourished individuals. In this syndrome, there are wide range of biochemical alterations, clinical manifestations, and complications, starting from mild (asymptomatic) to severe (death). This syndrome was initially proposed in 1950s; however, there is still no agreement for its clear definition, causing clinicians to be less aware and tend to overlook this condition. Clinical manifestations which usually appear include electrolyte imbalances (hypophosphatemia, hypokalemia, hyponatremia, hypomagnesemia) and vitamin B1 deficiency. The main principle in management of refeeding syndrome is prevention, where clinicians need to identify this condition in the early stage in high risk individuals, supervision during refeeding, and administration of appropriate diet.

Chronic Diarrhea Due to Intestinal Amyloidosis Lydia D Simatupang; Kharia Utia; Ari Fahrial Syam; Marcellus Simadibrata; Arya Govinda; Ening Krisnuhoni
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 6, ISSUE 3, December 2005
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/63200591-94

Amyloidosis is a rare disease, when diagnosed it’s incurable and mostly affect over 40 years old male. Diagnostic is confirmed if histopathologic stained positive with Congo red and evidence of monoclonal protein. Survivals for untreated patients are 13 months in primary amyloidosis but if secondary to other chronic disease and systemic, survival could be 3-4 years. It can not be prevented but when affected, control of the underlying illness can prevent progression of amyloidosis. We report a rare case of a 67 year old male, who came with chronic diarrhea. The stool analysis, there were no negative gram microorganisme found, only food maldigestion and fungus infection. Stool analyze from parasitology department were found microspore, but the stool culture were sterile. The patient underwent colonoscopy which revealed hyperemis mucosa in rectum, sigmoid, descending transverse colon. From the biopsy was concluded intestinal amyloidosis. We treated the patient symptomatically and couldn’t find the underlying inflammatory disease which causes the problem. Keywords: secondary amyloidosis, chronic diarrhea, malabsorption, colonoscopy, protein electrophoresis

Reduction of Liver Fibrosis After Treatment with Elbasvir/Grazoprevir in Patients with Hepatitis C Infection in Chronic Kidney Disease on Hemodialysis, a Quasi-Experimental Study Bayu Laksono; Nenny Agustanti; Rudi Supriyadi; Muhammad Begawan Bestari; Siti Aminah Abdurachman
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 22, No 1 (2021): VOLUME 22, NUMBER 1, April 2021
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Approximately 5-60% of hemodialysis patients have comorbid of hepatitis C virus (HCV) infection. The survival rate of hemodialysis patients HCV is lower than those without HCV due to the risk of liver fibrosis and cardiovascular disease. The combination of Elbasvir and Grazoprevir is the drug of choice for these patients with HCV genotype 1 and 4 which mainly inherited in populations in Indonesia. However, a high cost is required for this genome testing. Eradication of HCV might reduce liver fibrosis. One of the methods to evaluate liver fibrosis is by using APRI score. The aim of this study is to assess liver fibrosis using APRI score after Elbasvir/Grazoprevir therapy completion.Method: This was a quasi-experimental study without a control group which conducted during April-November 2019 in Dr. Hasan Sadikin Hospital, Bandung. Patients with reactive anti HCV, detected HCV RNA without genotype test, and sustained virological response (SVR) 12 achieved were included. APRI score and HCV RNA tests were performed before and after 12 weeks end of therapy (SVR12). The data were analyzed using paired T-test at a 95% confidence level.Results: Approximately 30% of hemodialysis patients had HCV infection. A total of 37 HCV patients in the hemodialysis unit were given Elbasvir/Grazoprevir for 12 weeks. The APRI score before and after 12 weeks after therapy were 0.336 and 0.270 (p = 0.002) respectively.Conclusion: The combination of Elbasvir/Grazoprevir might reduce the degree of liver fibrosis based on APRI score from 0.336 to 0.270 in HCV patients with chronic kidney disease on hemodialysis

Clinical Characteristics and Microbiological Profiles of Community-Acquired Intra-Abdominal Infections Nata Pratama Hardjo Lugito; Cucunawangsih Cucunawangsih; Andree Kurniawan; Margaret Merlyn Tjiang
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 15, No 1 (2014): VOLUME 15, NUMBER 1, April 2014
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Intra-abdominal infections (IAIs) have different aspects to consider. One important aspectis the microbiological analyses, especially in the era of broad spread of resistant microorganisms. The studywas designed to describe the clinical characteristics and microbiological profiles of community acquired IAIs. Method: An observational study was performed on medical records of 12 months period (January toDecember 2013) in a General Hospital, Karawaci, Tangerang. Adult patients undergoing surgery for IAIs with positive microbiological culture and identification of microorganisms were included. Data collected were clinical characteristics and microbiological profiles and wereanalyzed statisticallyusing the SPSS version 17. Results: In 12 months period of study, 17 patients of IAIs with a total of 17 intra peritoneal specimens were collected. A total of six microorganisms were cultured. All the IAIs were monomicrobial, with aerobicmicroorganism dominantly Gram-negative bacilli. The dominant microorganism was Escherichia coli (E.coli), found in 58.8% of IAIs. The most common site was appendix (41.2%), and none from small intestine. Thesusceptibility test found that piperacillin tazobactam, tigecycline, meropenem and amikacin were the most activeantimicrobial against E. coli. Multi-drug resistant (MDR) E. coli in this study was 40%. The MDR E. coli had66.6% resistance to levofloxacin and ciprofloxacin, 66.6% susceptibility to ceftriaxone and ceftazidime, and100.0% susceptibility to amikacin. Conclusion: The most common site of community-acquired IAIs was appendix (41.2%). E. coli is still adominant microorganism with the MDR E. coli proportion of 40%.Keywords: intra-abdominal infections, clinical characteristics, microbiological profiles

Page 45 of 78 | Total Record : 771

43 44 45 46 47

Filter by Year

2000 2025

Filter By Issues

All Issue Vol 26, No 2 (2025): VOLUME 26, NUMBER 2, AGUSTUS, 2025 Vol 26, No 1 (2025): VOLUME 26, NUMBER 1, April, 2025 Vol 25, No 3 (2024): VOLUME 25, NUMBER 3, December, 2024 Vol 25, No 2 (2024): VOLUME 25, NUMBER 2, August, 2024 Vol 25, No 1 (2024): VOLUME 25, NUMBER 1, April, 2024 Vol 24, No 3 (2023): VOLUME 24, NUMBER 3, December, 2023 Vol 24, No 2 (2023): VOLUME 24, NUMBER 2, August, 2023 Vol 24, No 1 (2023): VOLUME 24, NUMBER 1, April, 2023 Vol 23, No 3 (2022): VOLUME 23, NUMBER 3, December 2022 Vol 23, No 2 (2022): VOLUME 23, NUMBER 2, August 2022 Vol 23, No 1 (2022): VOLUME 23, NUMBER 1, April 2022 Vol 22, No 3 (2021): VOLUME 22, NUMBER 3, December 2021 Vol 22, No 2 (2021): VOLUME 22, NUMBER 2, August 2021 Vol 22, No 1 (2021): VOLUME 22, NUMBER 1, April 2021 Vol 21, No 3 (2020): VOLUME 21, NUMBER 3, December 2020 Vol 21, No 2 (2020): VOLUME 21, NUMBER 2, August 2020 Vol 21, No 1 (2020): VOLUME 21, NUMBER 1, April 2020 Vol 20, No 3 (2019): VOLUME 20, NUMBER 3, December 2019 Vol 20, No 2 (2019): VOLUME 20, NUMBER 2, August 2019 Vol 20, No 1 (2019): VOLUME 20, NUMBER 1, April 2019 Vol 19, No 3 (2018): VOLUME 19, NUMBER 3, December 2018 Vol 19, No 2 (2018): VOLUME 19, NUMBER 2, August 2018 Vol 19, No 1 (2018): VOLUME 19, NUMBER 1, April 2018 Vol 18, No 3 (2017): VOLUME 18, NUMBER 3, DECEMBER 2017 Vol 18, No 2 (2017): VOLUME 18, NUMBER 2, AUGUST 2017 Vol 18, No 1 (2017): VOLUME 18, NUMBER 1, April 2017 Vol 17, No 3 (2016): VOLUME 17, NUMBER 3, December 2016 Vol 17, No 2 (2016): VOLUME 17, NUMBER 2, August 2016 Vol 17, No 1 (2016): VOLUME 17, NUMBER 1, April 2016 Vol 16, No 3 (2015): VOLUME 16, NUMBER 3, December 2015 Vol 16, No 2 (2015): VOLUME 16, NUMBER 2, August 2015 Vol 16, No 1 (2015): VOLUME 16, NUMBER 1, April 2015 Vol 15, No 3 (2014): VOLUME 15, NUMBER 3, December 2014 Vol 15, No 2 (2014): VOLUME 15, NUMBER 2, August 2014 Vol 15, No 1 (2014): VOLUME 15, NUMBER 1, April 2014 VOLUME 14, NUMBER 3, December 2013 VOLUME 14, NUMBER 2, August 2013 VOLUME 14, NUMBER 1, April 2013 VOLUME 13, NUMBER 3, Desember 2012 VOLUME 13, NUMBER 2, August 2012 VOLUME 13, NUMBER 1, April 2012 VOLUME 12, NUMBER 3, December 2011 VOLUME 12, NUMBER 2, August 2011 VOLUME 12, NUMBER 1, April 2011 VOLUME 11, NUMBER 3, December 2010 VOLUME 11, NUMBER 2, August 2010 VOLUME 11, NUMBER 1, April 2010 VOLUME 10, NUMBER 3, December 2009 VOLUME 10, ISSUE 2, August 2009 VOLUME 10, ISSUE 1, April 2009 VOLUME 9, ISSUE 3, December 2008 VOLUME 9, ISSUE 2, August 2008 VOLUME 9, ISSUE 1, April 2008 VOLUME 8, ISSUE 3, December 2007 VOLUME 8 ISSUE 2 August 2007 VOLUME 8, ISSUE 1, April 2007 VOLUME 7, ISSUE 3, December 2006 VOLUME 7, ISSUE 2, August 2006 VOLUME 7, ISSUE 1, April 2006 VOLUME 6, ISSUE 3, December 2005 VOLUME 6, ISSUE 2, August 2005 VOLUME 6, ISSUE 1, April 2005 VOLUME 5, ISSUE 3, December 2004 VOLUME 5, ISSUE 2, August 2004 VOLUME 5, ISSUE 1, April 2004 VOLUME 4, ISSUE 3, December 2003 VOLUME 4, ISSUE 2, August 2003 VOLUME 4, NUMBER 1, April 2003 VOLUME 3, NUMBER 3, December 2002 VOLUME 3, NUMBER 2, August 2002 VOLUME 3, NUMBER 1, April 2002 VOLUME 2, NUMBER 3, December 2001 VOLUME 2, NUMBER 2, August 2001 VOLUME 2, NUMBER 1, April 2001 VOLUME 1, NUMBER 1, December 2000 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Murdani Abdullah

Contact Email
ina.jghe@gmail.com

Phone
+6285891498517

Journal Mail Official
ina.jghe@gmail.com

Editorial Address
Divisi Gastroenterologi, Departemen Ilmu Penyakit Dalam, FKUI/RSUPN Dr. Cipto Mangunkusumo, Jl. Diponegoro No. 71 Jakarta 10430 Indonesia

Location
Kota adm. jakarta pusat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Murdani Abdullah

Contact Email ina.jghe@gmail.com

Phone +6285891498517

Journal Mail Official ina.jghe@gmail.com

Editorial Address Divisi Gastroenterologi, Departemen Ilmu Penyakit Dalam, FKUI/RSUPN Dr. Cipto Mangunkusumo, Jl. Diponegoro No. 71 Jakarta 10430 Indonesia

Location Kota adm. jakarta pusat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Murdani Abdullah

Contact Email
ina.jghe@gmail.com

Phone
+6285891498517

Journal Mail Official
ina.jghe@gmail.com

Editorial Address
Divisi Gastroenterologi, Departemen Ilmu Penyakit Dalam, FKUI/RSUPN Dr. Cipto Mangunkusumo, Jl. Diponegoro No. 71 Jakarta 10430 Indonesia

Location
Kota adm. jakarta pusat,

Dki jakarta

INDONESIA